No OS Benefit from Continuous as Compared with Fixed-Duration Maintenance Therapy with Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - August 13, 2026 11 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENDURANCE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Cetuximab FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC MOST POPULAR 2023 ASCO Annual Meeting Research Round Up: Progress in Treating Breast... July 27, 2023 Efficacy of Rituximab Maintenance in Patients with Mantle Cell Lymphoma Who... November 28, 2023 The Benefits of Yoga During Cancer and How to Get Started August 2, 2022 Radiation Treatment Delivery Improved Using a Visualization of the Invisible Radiation... January 21, 2021 Load more HOT NEWS Preoperative ctDNA Levels Are Detectable in the Majority of Patients with... Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced... Ovarian Function Suppression Plus Tamoxifen Significantly Reduces Premenopausal Breast Cancer Recurrence... Children’s cancer charities team up for tomorrow’s treatments
